{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:01:35Z","timestamp":1783472495837,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U19AI113048"],"award-info":[{"award-number":["U19AI113048"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U19AI113048"],"award-info":[{"award-number":["U19AI113048"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U19AI113048"],"award-info":[{"award-number":["U19AI113048"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U19AI113048"],"award-info":[{"award-number":["U19AI113048"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U19AI113048"],"award-info":[{"award-number":["U19AI113048"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U19AI113048"],"award-info":[{"award-number":["U19AI113048"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The HIV-1 epidemic remains an urgent global health concern. Young women are disproportionately at risk of acquiring the virus. A range of highly effective, female-controlled, discrete vaginal products therefore is needed to help curb the epidemic. Oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are effective in HIV-1 pre-exposure prophylaxis (PrEP) and form a promising basis for a vaginal product. Here, we evaluate TDF and FTC in combination with the broadly neutralizing antibody VRC01-<jats:italic>N<\/jats:italic> using a highly reproducible humanized mouse model. The agents were vaginally dosed individually and in combination, and the efficacy of HIV-1 prevention was analyzed using the established, rigorous median-effect model. Surprisingly, the triple combination showed a high degree of synergism, unprecedented for in vivo HIV-1 PrEP, leading to a possible fivefold dose reduction for some of the agents. Vaginal administration of the TDF-FTC-VRC01-<jats:italic>N<\/jats:italic> combination holds significant promise for HIV-1 PrEP.<\/jats:p>","DOI":"10.1038\/s41598-020-69937-5","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T10:04:58Z","timestamp":1596449098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Highly synergistic drug combination prevents vaginal HIV infection in humanized mice"],"prefix":"10.1038","volume":"10","author":[{"given":"Marc M.","family":"Baum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjula","family":"Gunawardana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bobardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe A.","family":"Gallay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"69937_CR1","unstructured":"Fact Sheet\u2014World AIDS Day 2019 (UNAIDS, Geneva, Switzerland, 2019);\u00a0https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf. Accessed 9 Apr 2020"},{"key":"69937_CR2","unstructured":"Prevention Gap Report (UNAIDS, Geneva, Switzerland, 2016);\u00a0http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2016-prevention-gap-report_en.pdf.\u00a0Accessed 9 Apr 2020."},{"key":"69937_CR3","unstructured":"Fast-Track: Ending the AIDS Epidemic by 2030 (UNAIDS, Geneva, Switzerland, 2014); http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2016-prevention-gap-report_en.pdf. Accessed 9 Apr 2020."},{"key":"69937_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s0140-6736(19)31288-7","volume":"394","author":"K Ahmed","year":"2019","unstructured":"Ahmed, K. et al. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: A randomised, multicentre, open-label trial. Lancet 394, 303\u2013313. https:\/\/doi.org\/10.1016\/s0140-6736(19)31288-7 (2019).","journal-title":"Lancet"},{"key":"69937_CR5","unstructured":"Global PrEP Tracker (AVAC, New York, NY, USA, 2020);\u00a0https:\/\/www.prepwatch.org\/resource\/global-prep-tracker\/. Accessed 9 Apr 2020."},{"key":"69937_CR6","doi-asserted-by":"publisher","first-page":"e25250","DOI":"10.1002\/jia2.25250","volume":"22","author":"D Krakower","year":"2019","unstructured":"Krakower, D. et al. Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care. J. Int. AIDS Soc. 22, e25250. https:\/\/doi.org\/10.1002\/jia2.25250 (2019).","journal-title":"J. Int. AIDS Soc."},{"key":"69937_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz894","author":"DP Serota","year":"2019","unstructured":"Serota, D. P. et al. Pre-exposure prophylaxis uptake and discontinuation among young black men who have sex with men in Atlanta, Georgia: A prospective cohort study. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciz894 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"69937_CR8","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1097\/qai.0000000000002054","volume":"81","author":"J Zucker","year":"2019","unstructured":"Zucker, J. et al. Predictors of disengagement in care for individuals receiving pre-exposure prophylaxis (PrEP). J. Acquir. Immune Defic. Syndr. 81, e104\u2013e108. https:\/\/doi.org\/10.1097\/qai.0000000000002054 (2019).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"69937_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa037","author":"YA Huang","year":"2020","unstructured":"Huang, Y. A., Tao, G., Smith, D. K. & Hoover, K. W. Persistence with HIV preexposure prophylaxis in the United States, 2012\u20132017. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa037 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"69937_CR10","doi-asserted-by":"publisher","first-page":"e25283","DOI":"10.1002\/jia2.25283","volume":"22","author":"ET Montgomery","year":"2019","unstructured":"Montgomery, E. T. et al. End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: The Quatro Clinical Crossover Study. J. Int. AIDS Soc. 22, e25283. https:\/\/doi.org\/10.1002\/jia2.25283 (2019).","journal-title":"J. Int. AIDS Soc."},{"key":"69937_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1126\/science.1206399","volume":"333","author":"RJ Shattock","year":"2011","unstructured":"Shattock, R. J., Warren, M., McCormack, S. & Hankins, C. A. Turning the tide against HIV. Science 333, 42\u201343 (2011).","journal-title":"Science"},{"key":"69937_CR12","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nm.2649","volume":"18","author":"BL Jilek","year":"2012","unstructured":"Jilek, B. L. et al. A Quantitative Basis for Antiretroviral Therapy for HIV-1 Infection. Nat. Med. 18, 446\u2013451 (2012).","journal-title":"Nat. Med."},{"key":"69937_CR13","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1126\/science.1193748","volume":"329","author":"QA Karim","year":"2010","unstructured":"Karim, Q. A. et al. Effectiveness and safety of Tenofovir Gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168\u20131174 (2010).","journal-title":"Science"},{"key":"69937_CR14","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant, R. M. et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N. Engl. J. Med. 363, 2587\u20132599 (2010).","journal-title":"N. Engl. J. Med."},{"key":"69937_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten, J. M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399\u2013410. https:\/\/doi.org\/10.1056\/NEJMoa1108524 (2012).","journal-title":"N. Engl. J. Med."},{"key":"69937_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen, M. C. et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367, 423\u2013434. https:\/\/doi.org\/10.1056\/NEJMoa1110711 (2012).","journal-title":"N. Engl. J. Med."},{"key":"69937_CR17","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","volume":"381","author":"K Choopanya","year":"2013","unstructured":"Choopanya, K. et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 381, 2083\u20132090 (2013).","journal-title":"Lancet"},{"key":"69937_CR18","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","volume":"373","author":"JM Molina","year":"2015","unstructured":"Molina, J. M. et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N. Engl. J. Med. 373, 2237\u20132246. https:\/\/doi.org\/10.1056\/NEJMoa1506273 (2015).","journal-title":"N. Engl. J. Med."},{"key":"69937_CR19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/QAI.0000000000001129","volume":"73","author":"JL Marcus","year":"2016","unstructured":"Marcus, J. L. et al. Preexposure prophylaxis for HIV prevention in a large integrated health care system: Adherence, renal safety, and discontinuation. J. Acquir. Immune Defic. Syndr. 73, 540\u2013546 (2016).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"69937_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s0140-6736(15)00056-2","volume":"387","author":"S McCormack","year":"2016","unstructured":"McCormack, S. et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 387, 53\u201360. https:\/\/doi.org\/10.1016\/s0140-6736(15)00056-2 (2016).","journal-title":"Lancet"},{"key":"69937_CR21","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1097\/qad.0000000000001521","volume":"31","author":"DJ Anderson","year":"2017","unstructured":"Anderson, D. J. et al. Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV. Aids 31, 1505\u20131517. https:\/\/doi.org\/10.1097\/qad.0000000000001521 (2017).","journal-title":"Aids"},{"key":"69937_CR22","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1126\/science.1192819","volume":"329","author":"T Zhou","year":"2010","unstructured":"Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811\u2013817. https:\/\/doi.org\/10.1126\/science.1192819 (2010).","journal-title":"Science"},{"key":"69937_CR23","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","volume":"329","author":"X Wu","year":"2010","unstructured":"Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856\u2013861. https:\/\/doi.org\/10.1126\/science.1187659 (2010).","journal-title":"Science"},{"key":"69937_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme Inhibitors. Adv. Enzyme Regul. 22, 27\u201355. https:\/\/doi.org\/10.1016\/0065-2571(84)90007-4 (1984).","journal-title":"Adv. Enzyme Regul."},{"key":"69937_CR25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681. https:\/\/doi.org\/10.1124\/pr.58.3.10 (2006).","journal-title":"Pharmacol. Rev."},{"key":"69937_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/pbi.12137","volume":"12","author":"AYH Teh","year":"2014","unstructured":"Teh, A. Y. H., Maresch, D., Klein, K. & Ma, J. K. C. Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco. Plant Biotechnol. J. 12, 300\u2013311. https:\/\/doi.org\/10.1111\/pbi.12137 (2014).","journal-title":"Plant Biotechnol. J."},{"key":"69937_CR27","doi-asserted-by":"publisher","first-page":"e0184303","DOI":"10.1371\/journal.pone.0184303","volume":"12","author":"PA Gallay","year":"2017","unstructured":"Gallay, P. A. et al. Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice. PLoS ONE 12, e0184303. https:\/\/doi.org\/10.1371\/journal.pone.0184303 (2017).","journal-title":"PLoS ONE"},{"key":"69937_CR28","doi-asserted-by":"publisher","first-page":"e4879","DOI":"10.1136\/bmj.e4879","volume":"345","author":"B Roehr","year":"2012","unstructured":"Roehr, B. FDA approves first drug to prevent HIV infection. B. M. J. 345, e4879 (2012).","journal-title":"B. M. J."},{"key":"69937_CR29","doi-asserted-by":"publisher","first-page":"e0157061","DOI":"10.1371\/journal.pone.0157061","volume":"11","author":"P Srinivasan","year":"2016","unstructured":"Srinivasan, P. et al. Topical delivery of tenofovir disoproxil fumarate and emtricitabine from pod-intravaginal rings protect macaques from multiple SHIV exposures. PLoS ONE 11, e0157061 (2016).","journal-title":"PLoS ONE"},{"key":"69937_CR30","doi-asserted-by":"publisher","first-page":"e1002655","DOI":"10.1371\/journal.pmed.1002655","volume":"15","author":"KL Vincent","year":"2018","unstructured":"Vincent, K. L. et al. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A phase I trial. PLoS Med. 15, e1002655 (2018).","journal-title":"PLoS Med."},{"key":"69937_CR31","doi-asserted-by":"publisher","first-page":"e0201952","DOI":"10.1371\/journal.pone.0201952","volume":"13","author":"KL Vincent","year":"2018","unstructured":"Vincent, K. L. et al. Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc. PLoS ONE 13, e0201952 (2018).","journal-title":"PLoS ONE"},{"key":"69937_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.virol.2012.06.025","volume":"432","author":"M Veselinovic","year":"2012","unstructured":"Veselinovic, M., Neff, C. P., Mulder, L. R. & Akkina, R. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology 432, 505\u2013510 (2012).","journal-title":"Virology"},{"key":"69937_CR33","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00705-016-2942-4","volume":"161","author":"M Sun","year":"2016","unstructured":"Sun, M. et al. VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice. Arch. Virol. 161, 2449\u20132455. https:\/\/doi.org\/10.1007\/s00705-016-2942-4 (2016).","journal-title":"Arch. Virol."},{"key":"69937_CR34","first-page":"e02465","volume":"61","author":"C Zhao","year":"2017","unstructured":"Zhao, C. et al. Pharmacokinetics and preliminary safety of pod-intravaginal rings delivering the monoclonal antibody VRC01-N for HIV prophylaxis in a Macaque Model. Antimicrob. Agents Chemother. 61, e02465-e12466 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69937_CR35","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1128\/AAC.01972-13","volume":"58","author":"H Cai","year":"2014","unstructured":"Cai, H. et al. In vitro combination of anti-cytomegalovirus compounds acting through different targets: Role of the slope parameter and insights into mechanisms of action. Antimicrob. Agents Chemother. 58, 986\u2013994. https:\/\/doi.org\/10.1128\/AAC.01972-13 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69937_CR36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1182\/blood-2005-11-4388","volume":"108","author":"P Lan","year":"2006","unstructured":"Lan, P., Tonomura, N., Shimizu, A., Wang, S. & Yang, Y.-G. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus\/liver and CD34+ cell transplantation. Blood 108, 487\u2013492. https:\/\/doi.org\/10.1182\/blood-2005-11-4388 (2006).","journal-title":"Blood"},{"key":"69937_CR37","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/nm1431","volume":"12","author":"MW Melkus","year":"2006","unstructured":"Melkus, M. W. et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 12, 1316\u20131322 (2006).","journal-title":"Nat. Med."},{"key":"69937_CR38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1084\/jem.20062411","volume":"204","author":"ZF Sun","year":"2007","unstructured":"Sun, Z. F. et al. Intrarectal transmission, systemic infection, and CD4(+) T cell depletion in humanized mice infected with HIV-1. J. Exp. Med. 204, 705\u2013714 (2007).","journal-title":"J. Exp. Med."},{"key":"69937_CR39","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.virol.2011.05.013","volume":"15","author":"CA Stoddart","year":"2011","unstructured":"Stoddart, C. A. et al. Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD-scid IL-2R\u03b3(\u2212\/\u2212) (NSG) BLT mice. Virology 15, 154\u2013160 (2011).","journal-title":"Virology"},{"key":"69937_CR40","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/mi.2012.31","volume":"5","author":"PW Denton","year":"2012","unstructured":"Denton, P. W. et al. IL-2 receptor gamma-chain molecule is critical for intestinal T-cell reconstitution in humanized mice. Mucosal Immunol. 5, 555\u2013566 (2012).","journal-title":"Mucosal Immunol."},{"key":"69937_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1371\/journal.pmed.0050016","volume":"5","author":"PW Denton","year":"2008","unstructured":"Denton, P. W. et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5, 79\u201389 (2008).","journal-title":"PLoS Med."},{"key":"69937_CR42","doi-asserted-by":"publisher","first-page":"e8829","DOI":"10.1371\/journal.pone.0008829","volume":"5","author":"PW Denton","year":"2010","unstructured":"Denton, P. W. et al. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS ONE 5, e8829 (2010).","journal-title":"PLoS ONE"},{"key":"69937_CR43","doi-asserted-by":"publisher","first-page":"7582","DOI":"10.1128\/jvi.00537-11","volume":"85","author":"PW Denton","year":"2011","unstructured":"Denton, P. W. et al. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J. Virol. 85, 7582\u20137593. https:\/\/doi.org\/10.1128\/jvi.00537-11 (2011).","journal-title":"J. Virol."},{"key":"69937_CR44","doi-asserted-by":"publisher","first-page":"e60024","DOI":"10.1371\/journal.pone.0060024","volume":"8","author":"ML Chateau","year":"2013","unstructured":"Chateau, M. L., Denton, P. W., Swanson, M. D., McGowan, I. & Garcia, J. V. Rectal transmission of transmitted\/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice. PLoS ONE 8, e60024. https:\/\/doi.org\/10.1371\/journal.pone.0060024 (2013).","journal-title":"PLoS ONE"},{"key":"69937_CR45","volume-title":"PC Software and User's Guide: A Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations, and the Determination of IC50 and ED50 and LD50 Values","author":"CompuSyn for Drug Combinations","year":"2005","unstructured":"CompuSyn for Drug Combinations. PC Software and User\u2019s Guide: A Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations, and the Determination of IC\n50 and ED\n50 and LD\n50 Values Values (ComboSyn Inc, Paramus, 2005)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69937-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69937-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69937-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T15:36:06Z","timestamp":1670340966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69937-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["69937"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-69937-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"28 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12995"}}